Phase IIIb Enerzair Breezhaler ARGON study meets primary endpoint

6 June 2020

The Phase IIIb ARGON study met its primary endpoint, demonstrating non-inferiority of once-daily Enerzair Breezhaler (QVM149) versus a free combination of twice-daily, two-inhaler standard-of-care regimen in treating uncontrolled asthma, says Swiss pharma giant Novartis (NOVN: VX). The full results were published online in Respiratory Medicine.

If approved, once-daily Enerzair Breezhaler will be the first long-acting beta2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS treatment and could provide an effective and convenient alternative to the current standard-of-care regimen through a single inhaler, once a day regimen, according to Novartis, whose shares closed up 1.55% at 83.04 Swiss francs on Friday.

Enerzair Breezhaler consists of a fixed dose combination of three active substances (indacaterol/glycopyrronium/mometasone; IND/GLY/MF) in capsules, to be administered using an inhaler.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK